have not been reported. We investigated whether centrally administered GIP could increase 48 peripheral plasma GIP concentrations and influence the metabolic response to a mixed 49 macronutrient meal in nonhuman primates. An infusion and sampling system was developed to 50 enable continuous intracerebroventricular (ICV) infusions with serial venous sampling in 51 conscious nonhuman primates. Male baboons (Papio Sp.) that were healthy and had normal 52 body weights (28.9 ±2.1Kg) were studied (n=3). Animals were randomized to receive continuous 
INTRODUCTION

71
Glucose-dependent insulinotropic polypeptide (GIP) is a 42 amino acid peptide released 72 primarily from the enteroendocrine K-cells in response to nutrient stimulation. Although 73 originally described for its role in gastric acid secretion (5) , GIP is an important incretin peptide 74 and an essential driver of normal postprandial insulin secretion (17) . Beyond its insulinotropic 75 and intestinal actions, GIP also has effects on adipose tissue, bone, the heart and vasculature, 76 pancreatic α-cells, and, importantly, on the central nervous system (8) . 77 The GIP receptor (GIPR) is expressed in multiple regions of the mammalian brain (32, 45) 78 and immunohistochemically detected GIP has also been shown in the rat brain (36) . Brain GIP 79 action is now linked to neurotrophic effects and augmented synaptic plasticity in rodents (20) (21) (22) 80 29, 31, 39, 44, 53) . Whether central GIP signaling can generate effects outside of the central 81 nervous system is unclear (2, 16, 38) . In support of such an action for GIP, other metabolically 82 active intestinal peptides (6, 41) are known to generate peripheral effects through actions in the 83 brain and, thereby, modulate metabolic function through the gut-brain axis.
84
A series of recent studies in a canine model has provided evidence for a brain-gut 85 signaling pathway capable of modulating GIP concentrations in the peripheral circulation. These 86 studies showed that plasma GIP concentrations were increased by intracerebroventricular (ICV) 87 administration of neuropeptide Y (48), bombesin (51) , and neurotensin (50) and decreased by 88 ICV insulin (49) . Earlier studies also demonstrated nutrient-independent effects of bombesin-like 89 peptides on GIP release in enteroendocrine cell lines, suggesting an independent neural 90 influence on GIP secretion from K-cells (35) . Combined, these studies support a role for 91 neuroregulation in peripheral GIP release and indicate the presence of an efferent signal from 92 the brain to the gut that can modulate GIP release independent of nutrient stimulation. 93 We investigated whether centrally administered GIP could increase peripheral plasma GIP 94 concentrations and influence the metabolic response to a mixed macronutrient meal in 95 conscious healthy nonhuman primates. We present evidence that central nervous system GIP 96 signaling generates an efferent signal that stimulates GIP release into the peripheral circulation 97 and influences postprandial islet peptide secretion. 
117
Tether system adaptation period. After an initial period of acclimation to the indoor 118 housing environment, n=12 animals (initial selection pool) were evaluated for adaptation to 119 single caging and to the presence of a tether jacket and tether coil for a period of 3 weeks. This 120 "sham tethering" approach has been described in detail elsewhere (14) . In brief, each animal 121 was fitted to a customized cotton tether jacket which was connected to a stainless-steel coil 122 that "tethered" the animal to the cage ceiling. During this period, the animals were assessed 123 daily for behavior and food intake and were sedated weekly for physical and biochemical health 124 assessments and to enable adjustments to the tethering system to ensure optimal comfort and 125 functionality. Four animals were selected based on technician-and investigator-determined 126 habituation to the housing environment and tether system. These animals then underwent the following procedures in preparation for study : 1) overview of the study is presented in Figure 1A . The experiments undertaken involved 131 modification of an extant vascular infusion and sampling system (3, 14) was connected through the tethering system and kept patent using a continuous heparinized 207 saline (5U/ml) infusion from a volumetric infusion pump maintained at the top of the cage, as 208 described previously (14) . In parallel, the ICV infusion line was also routed through the tether 209 coil to the infusion system at the top of the cage. The ICV line was kept patent using a period. One animal failed to adapt to the tether system and was removed from study before 243 initiation of the experimental phase. The remaining animals (n=3) adapted fully to the tether 244 system, had normal food and water intakes, and were weight stable before initiation of the 245 mixed-meal metabolic studies.
246
GIP peptide. Human GIP (1-42) peptide (Bachem, Torrence, CA) was used for ICV infusion.
247
Peptide was added to aCSF vehicle with corrections for purity. We have found that the GIP 248 peptide (1-42) coding region of the baboon GIP gene has 100% identity with the human ortholog.
249
Baboon and human GIPR gene exon sequences also have a high degree of identity. 
RESULTS
358
Basic descriptive data are presented in Table 2 . Baboons were young adult males 11yrs.) with normal body weight and normal metabolic status. Body weight was stable during were present throughout the study period. One animal did not go forward into the experimental 364 phase of the study because of system compatibility issues and was released from study. Data on 365 this animal are not included and data from the remaining n=3 animals were analyzed.
366
Fasted GIP concentrations and GIP AUC values are presented in Table 3 . ICV GIP infusion Table 4 ).
378
The mean±SE INS concentrations over the experimental period in control and ICV GIP condition 379 are shown in Figure 3A . 380 Fasted glucagon and glucagon AUCs are shown in the second third panel of Table 4 . concentrations over the experimental period are shown in Figure 3C . 391 Glucose, triglyceride, and free fatty acid concentrations in the fasted AUCs are shown in 392 been shown to generate a signal that promotes its own secretion from the β-cell (10, 47, 49 Our data add to the current literature on the metabolic effects of central GIP signaling. to reflect an increase in cholinergic input to the pancreatic islets (42) . Conflicting data have been 470 published regarding the influence of the parasympathetic nervous system on GIP release (52) but the weight of evidence favors non-cholinergic involvement in GIP secretion. Moreover, 472 evidence from human studies indicates that peripheral GIP administration increases PP 473 concentrations (1, 11, 13) . Therefore, the most parsimonious explanation is that the increase in 474 PP was attributable to the increased peripheral GIP concentrations and not directly by central 475 GIP action. Furthermore, the increase in plasma GIP was also likely to be the direct cause of the 476 higher postprandial insulin concentrations that occurred under ICV GIP. We did not find and insulin with ICV GIP suggests that central GIP signaling was able to influence both peptides 482 indirectly by promoting peripheral GIP release.
483
A weakness of our study is that we were unable to quantify whether there was any GIP 484 spillover from the CSF during our ICV infusion. Our ICV dose of GIP (100ng.kg differences (37) . In humans, a direct intravenous infusion of GIP at a dose 3 times that chosen in 491 our study was required to raise plasma total GIP concentrations up to a maximum of ≈50% of 492 those seen in our study (30). Furthermore, in a study by Chia et al. (12) in humans, a 12-fold 493 higher i.v. GIP infusion rate than the ICV infusion rate we used in baboons resulted in a 10-fold 494 increase in plasma total GIP from baseline which is comparable to the plasma GIP increase that 495 we observed in baboons. Therefore, it is unlikely that our dose of GIP was large enough and 496 unlikely that it would have entered the vasculature fast enough to explain the rate and extent of 497 the plasma GIP increase observed. Furthermore, a 2.0pmol.kg infusions to be undertaken using implantable osmotic pumps (3, 4, 43) . The ICV infusion system 511 described herein enables greater control over the dose quantity, timing, and duration.
512
In summary, we found that ICV administered GIP increased peripheral GIP Elimination and degradation of glucagon-like peptide-1 and glucose-dependent 
